Cost-effectiveness analysis of C-GALAD for early hepatocellular carcinoma screening in HBV-related cirrhotic patients in China

Imagine the human liver as a busy, bustling factory that keeps your body running smoothly. Sometimes, due to long-term infections like the Hepatitis B virus, this factory gets damaged and turns into a scarred, stiff version of itself called cirrhosis. In this damaged state, there's a real risk that a rogue, cancerous section might start growing inside the factory. This cancer is called hepatocellular carcinoma (HCC). The tricky part is that in its early stages, this cancer is like a sneaky ghost; it doesn't make noise or cause pain, so by the time you notice it, it's often too late to fix easily.

To catch these ghosts early, doctors use a "security system." The old, standard security guard is a test called AFP (alpha-fetoprotein) and a camera called an ultrasound (US). But sometimes, the ghost is too good at hiding, and the old guard misses it. Newer, smarter security systems have been invented that use a team of different detectors (biomarkers) working together to spot the trouble sooner. The big question for health officials and taxpayers is: Is it worth the extra money to upgrade to these fancy new systems? If we spend more now to catch the cancer earlier, do we save enough money and lives later to make it a good deal? This is the puzzle scientists call "cost-effectiveness analysis."

---

The Great Liver Detective Race

In this study, a team of researchers from China decided to play detective with a computer simulation to see which liver screening strategy is the best bang for the buck. They focused on a specific group: people in China who already have a damaged liver (cirrhosis) caused by the Hepatitis B virus. These folks are at high risk, so they need regular check-ups.

The researchers built a virtual world—a "decision tree" and a "Markov model"—to simulate the lives of a huge group of these patients over 30 years. They didn't just guess; they fed the computer real numbers about how well different tests work (sensitivity and specificity), how much they cost, and how much they improve a patient's quality of life (measured in something called QALYs, or "quality-adjusted life-years").

They pitted several "detective teams" against each other:

1. The Old Guard: Just the AFP blood test.
2. The Team-Up: AFP combined with another marker called DCP.
3. The Super Team: A mix of three markers (AFP, AFP-L3%, and DCP).
4. The New Star (C-GALAD): A sophisticated formula combining age, gender, and three specific blood markers.
5. The Camera Crew: All of the above, but paired with an ultrasound scan.

The goal was to see which team could find the most cancer cases early, keep patients alive and healthy the longest, and do it without breaking the bank. The researchers set a "price limit" for what they considered a good deal: spending up to three times China's 2024 per capita GDP (which is USD 13,448) for every extra year of healthy life gained.

The Results: Who Wins the Race?

When the computer simulation ran the race, the results were pretty clear.

The Biomarker Winner:
The C-GALAD strategy (the smart blood test formula without the camera) came out on top as the most cost-effective way to screen using blood tests alone.

• Compared to the old AFP test, C-GALAD cost an extra USD 1,567 for every extra healthy year gained.
• Compared to the "Super Team" (AFP + AFP-L3% + DCP), it cost an extra USD 4,499 per healthy year.
• Compared to the GALAD formula (without the "C" adjustment), C-GALAD was even better: it actually cost less money and gave patients more healthy years. In the world of economics, this is called "dominating" the other strategy.
• All these costs were well below the USD 13,448 limit, meaning they are a great value.

The Camera Crew Winner:
When the researchers added the ultrasound camera to the mix, the GALAD + US strategy was the clear winner compared to the old AFP + US method.

• This combination cost an extra USD 4,648 for every extra healthy year gained, which is also well under the price limit.

How Sure Are They?
The researchers didn't just take a single guess. They ran thousands of simulations, changing the numbers slightly each time to see if the results would flip-flop. They found that in 100% of these simulations, C-GALAD and GALAD + US were the most cost-effective choices. The things that mattered most to the results were how good the tests were at finding cancer (sensitivity), how good they were at ignoring healthy people (specificity), and the discount rate used for money over time.

What This Means (and What It Doesn't)

The study suggests that for patients with Hepatitis B-related cirrhosis in China, switching to the C-GALAD blood test (or GALAD + US) is a smart financial and health move. It's like upgrading from a basic flashlight to a high-tech thermal camera; you might pay a bit more upfront, but you catch the intruder (cancer) so early that you save a fortune on repairs later.

However, the authors are careful to note a few things. They didn't actually test these strategies on real people in a hospital for this specific study; they used a computer model based on existing data. They also pointed out that they didn't directly simulate the "C-GALAD + US" combo (the super smart blood test plus the camera), so while they suspect that would be even better, they can't prove it yet with this specific model.

In short, the paper concludes that C-GALAD is the best "blood-only" option, and GALAD + US is a great "blood-plus-camera" option. Both are affordable enough to be used widely, potentially helping doctors catch liver cancer before it becomes a monster, saving lives, and keeping healthcare costs in check.